Your browser is no longer supported. Please, upgrade your browser.
Alnylam Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-7.55 Insider Own0.20% Shs Outstand117.08M Perf Week-1.90%
Market Cap20.96B Forward P/E- EPS next Y-3.60 Insider Trans-29.42% Shs Float116.82M Perf Month5.56%
Income-876.40M PEG- EPS next Q-1.61 Inst Own94.80% Short Float3.61% Perf Quarter27.23%
Sales570.90M P/S36.72 EPS this Y8.00% Inst Trans0.30% Short Ratio6.83 Perf Half Y18.91%
Book/sh7.91 P/B22.62 EPS next Y41.40% ROA-26.30% Target Price174.78 Perf Year18.42%
Cash/sh14.59 P/C12.26 EPS next 5Y46.09% ROE-76.90% 52W Range119.29 - 184.83 Perf YTD37.68%
Dividend- P/FCF- EPS past 5Y-16.70% ROI-68.80% 52W High-3.19% Beta1.19
Dividend %- Quick Ratio4.80 Sales past 5Y64.40% Gross Margin84.60% 52W Low50.00% ATR5.64
Employees1453 Current Ratio5.00 Sales Q/Q78.50% Oper. Margin- RSI (14)56.29 Volatility2.86% 3.07%
OptionableYes Debt/Eq0.21 EPS Q/Q-5.80% Profit Margin- Rel Volume0.65 Prev Close181.83
ShortableYes LT Debt/Eq0.21 EarningsAug 03 BMO Payout- Avg Volume618.35K Price178.94
Recom2.30 SMA201.35% SMA508.68% SMA20022.00% Volume402,689 Change-1.59%
Feb-22-21Downgrade Guggenheim Buy → Neutral $162
Feb-12-21Reiterated H.C. Wainwright Buy $225 → $235
Feb-12-21Downgrade Citigroup Buy → Neutral $170 → $175
Jan-25-21Downgrade BMO Capital Markets Outperform → Market Perform $185
Sep-30-20Resumed Berenberg Hold $145
Sep-08-20Initiated Citigroup Buy $170
Aug-11-20Downgrade Oppenheimer Outperform → Perform
May-13-20Initiated RBC Capital Mkts Sector Perform $150
May-07-20Downgrade JP Morgan Overweight → Neutral $133 → $137
Apr-24-20Resumed Evercore ISI Outperform $160
Mar-19-20Initiated Berenberg Buy $200
Dec-19-19Reiterated Chardan Capital Markets Buy $150 → $190
Nov-20-19Initiated Oppenheimer Outperform $128
Nov-13-19Initiated BofA/Merrill Buy $110
May-23-19Resumed Goldman Neutral $80
Apr-12-19Initiated Evercore ISI Outperform
Mar-06-19Upgrade Evercore ISI In-line → Outperform
Mar-05-19Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-23-19Initiated UBS Neutral $87
Oct-01-18Initiated Cantor Fitzgerald Overweight $135
Jul-30-21 09:29AM  
Jul-29-21 05:00PM  
Jul-27-21 03:02PM  
Jul-21-21 08:00AM  
Jul-19-21 03:47PM  
Jul-06-21 10:06AM  
Jul-05-21 01:32AM  
Jul-01-21 06:56AM  
Jun-30-21 07:00AM  
Jun-28-21 10:39AM  
Jun-26-21 01:07PM  
Jun-25-21 10:28AM  
Jun-24-21 07:00AM  
Jun-23-21 07:00AM  
Jun-22-21 06:41AM  
Jun-07-21 07:30AM  
Jun-01-21 07:00AM  
May-26-21 04:00PM  
May-21-21 01:52AM  
May-11-21 07:00AM  
May-04-21 08:00AM  
May-03-21 07:00AM  
Apr-30-21 10:56AM  
Apr-29-21 05:01PM  
Apr-22-21 12:33PM  
Apr-19-21 02:00PM  
Apr-15-21 08:00AM  
Apr-12-21 08:43AM  
Apr-11-21 10:28AM  
Apr-08-21 09:04AM  
Apr-06-21 08:00AM  
Apr-01-21 08:55AM  
Mar-31-21 05:00PM  
Mar-29-21 03:01PM  
Mar-23-21 08:00AM  
Mar-22-21 01:19AM  
Mar-17-21 11:47AM  
Mar-11-21 08:30AM  
Mar-09-21 08:00AM  
Feb-22-21 04:00PM  
Feb-18-21 04:00PM  
Feb-12-21 10:06AM  
Feb-11-21 01:30PM  
Feb-10-21 10:52AM  
Feb-05-21 12:16AM  
Jan-28-21 08:00AM  
Jan-27-21 10:08AM  
Jan-11-21 04:29PM  
Jan-10-21 01:00PM  
Jan-08-21 09:57AM  
Jan-07-21 07:00AM  
Jan-04-21 04:00PM  
Dec-21-20 11:37PM  
Dec-20-20 03:14PM  
Dec-17-20 04:21PM  
Dec-15-20 07:00AM  
Dec-14-20 03:51PM  
Dec-08-20 08:00AM  
Dec-07-20 07:30AM  
Dec-05-20 11:31AM  
Dec-04-20 11:06AM  
Dec-03-20 01:52PM  
Nov-30-20 08:54AM  
Nov-25-20 01:16PM  
Nov-24-20 08:12AM  
Nov-20-20 10:08AM  
Nov-19-20 07:00AM  
Nov-13-20 09:00AM  
Nov-07-20 07:24AM  
Nov-06-20 10:48AM  
Nov-05-20 10:01PM  
Nov-04-20 08:30AM  
Nov-03-20 01:14PM  
Nov-02-20 04:00PM  
Oct-31-20 08:00AM  
Oct-30-20 07:00AM  
Oct-29-20 03:06PM  
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; lumasiran for the treatment of advanced PH1 and recurrent renal stones; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG to develop, manufacture, and commercialize RNAi therapeutics for the treatment of proprotein convertase subtilisin/kexin type 9, hypercholesterolemia, and other human diseases; with Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics to treat SARS-CoV-2, the virus that causes the disease COVID-19; Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational RNAi therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease; and with Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KEATING LAURIEEVP, Chief Legal OfficerJul 12Option Exercise87.906,812598,77011,944Jul 14 04:58 PM
KEATING LAURIEEVP, Chief Legal OfficerJul 12Sale178.966,8121,219,0985,132Jul 14 04:58 PM
Vaishnaw AkshayPresident, R&DJun 18Option Exercise61.2911,804723,49525,923Jun 22 04:07 PM
Vaishnaw AkshayPresident, R&DJun 18Sale175.0014,7082,573,90011,215Jun 22 04:07 PM
KEATING LAURIEEVP, Chief Legal OfficerJun 09Sale154.001,734267,0365,132Jun 11 04:13 PM
MARAGANORE JOHNChief Executive OfficerMay 13Option Exercise7.1033,979241,251248,744May 17 07:25 PM
MARAGANORE JOHNChief Executive OfficerMay 13Sale130.7833,9794,443,725214,765May 17 07:25 PM
Vaishnaw AkshayPresident, R&DApr 21Sale136.952,732374,13514,119Apr 21 06:22 PM
Vaishnaw AkshayPresident, R&DApr 19Sale137.673,706510,19219,202Apr 21 06:22 PM
MARAGANORE JOHNChief Executive OfficerFeb 25Option Exercise7.1033,979241,251240,015Feb 26 04:03 PM
MARAGANORE JOHNChief Executive OfficerFeb 25Sale147.3133,9795,005,421206,036Feb 26 04:03 PM
KEATING LAURIEEVP, Chief Legal OfficerJan 13Option Exercise82.459,027744,29011,261Jan 15 04:03 PM
KEATING LAURIEEVP, Chief Legal OfficerJan 13Sale169.909,0271,533,6982,234Jan 15 04:03 PM
KEATING LAURIEEVP, Chief Legal OfficerJan 12Option Exercise72.8314,9411,088,14917,175Jan 13 04:05 PM
Greenstreet YvonnePresident & COOJan 12Option Exercise42.223,125131,9387,945Jan 13 04:04 PM
KEATING LAURIEEVP, Chief Legal OfficerJan 12Sale160.2014,9412,393,6192,234Jan 13 04:05 PM
Greenstreet YvonnePresident & COOJan 12Sale161.003,125503,1254,820Jan 13 04:04 PM
KEATING LAURIEEVP, Chief Legal OfficerJan 11Sale154.00758116,7322,234Jan 13 04:05 PM
PAUL STEVEN MDirectorDec 18Option Exercise9.3015,000139,50016,000Dec 22 04:02 PM
PAUL STEVEN MDirectorDec 18Sale140.0015,0002,100,0001,000Dec 22 04:02 PM
SHARP PHILLIP ADirectorNov 25Option Exercise9.3030,000279,000265,633Nov 30 04:03 PM
SHARP PHILLIP ADirectorNov 25Sale124.8930,0003,746,749235,633Nov 30 04:03 PM
MARAGANORE JOHNChief Executive OfficerNov 19Option Exercise9.1434,765317,752232,354Nov 20 04:02 PM
MARAGANORE JOHNChief Executive OfficerNov 19Sale124.2334,7654,319,025197,589Nov 20 04:02 PM
Vaishnaw AkshayPresident, R&DSep 29Option Exercise42.2297140,99615,090Oct 01 04:03 PM
Vaishnaw AkshayPresident, R&DSep 29Sale140.00971135,94014,119Oct 01 04:03 PM
Greene Barry EPresidentSep 09Option Exercise9.1444,530407,004114,873Sep 11 05:11 PM
Greene Barry EPresidentSep 09Sale123.2344,5305,487,59470,343Sep 11 05:11 PM
MARAGANORE JOHNChief Executive OfficerAug 20Option Exercise9.1434,765317,752232,354Aug 21 04:06 PM
MARAGANORE JOHNChief Executive OfficerAug 20Sale136.1334,7654,732,542197,589Aug 21 04:06 PM
Greene Barry EPresidentAug 10Option Exercise70.954,931349,87167,167Aug 11 04:09 PM